Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
1998-11-3
|
pubmed:abstractText |
Salicylate hydroxylation using hydroxyl free radicals results into formation of 2,3-dihydroxybenzoic acid, 2,5-dihydroxybenzoic acid and catechol. Inspite of the fact that in vitro experiments have shown that catechol is a minor product, we have shown by these in vivo studies that it is a substantial product. Since catechol as well as 2,3-dihydroxybenzoic acid have not been found to be produced enzymatically from salicylates, they appear useful as in vivo indicators for monitoring hydroxyl free radicals. Administration of 1-methyl-4-phenylpyridinium ion (MPP+) to rat striatum using microdialysis results into the formation of hydroxyl radicals. Salicylate perfusion enables the estimation of the three derivatives cited above. They increased significantly after MPP+ administration in comparison to the baseline values, with catechol being the most significant. The maximum amounts were achieved 60 min after MPP+ administration, and the mean percentage increase at this time point were 83.1% for 2,3-DBA (n = 6, P = 0.005), 81.25% for 2,5-DBA (n = 6, P = 0.011) and 1228.8% for catechol (n = 4, p = 0.00008). MPP+ caused substantial decrease of dopamine metabolites. Dihydroxyphenylacetic acid decreased to 13% and homovanillic acid to 11.4%. We conclude that catechol is an important indicator of hydroxyl free radical formation in this animal model which is well suited to study the role of free radicals in Parkinsonism.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/1-Methyl-4-phenylpyridinium,
http://linkedlifedata.com/resource/pubmed/chemical/Catechols,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyl Radical,
http://linkedlifedata.com/resource/pubmed/chemical/Salicylates,
http://linkedlifedata.com/resource/pubmed/chemical/catechol
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0378-7966
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
23
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
137-42
|
pubmed:dateRevised |
2011-2-2
|
pubmed:meshHeading |
pubmed-meshheading:9725471-1-Methyl-4-phenylpyridinium,
pubmed-meshheading:9725471-Animals,
pubmed-meshheading:9725471-Catechols,
pubmed-meshheading:9725471-Disease Models, Animal,
pubmed-meshheading:9725471-Hydroxyl Radical,
pubmed-meshheading:9725471-Hydroxylation,
pubmed-meshheading:9725471-Male,
pubmed-meshheading:9725471-Microdialysis,
pubmed-meshheading:9725471-Parkinson Disease,
pubmed-meshheading:9725471-Rats,
pubmed-meshheading:9725471-Rats, Wistar,
pubmed-meshheading:9725471-Salicylates,
pubmed-meshheading:9725471-Visual Cortex
|
pubmed:articleTitle |
Catechol is the major product of salicylate hydroxylation in 1-methyl-4-phenylpyridinium ion treated rats.
|
pubmed:affiliation |
Katholieke Universiteit Leuven, Laboratorium voor Farmacotechnologie en Biofarmacie, Belgium.
|
pubmed:publicationType |
Journal Article
|